NDATOPICALSOLUTION
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
KERYDIN (tavaborole) by R-Pharm US is protein synthesis inhibitors [moa]. First approved in 2014.
Drug data last refreshed 4h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERYDIN (tavaborole) is a topical antifungal solution approved in 2014 for the treatment of onychomycosis (fungal nail infection). It works as a protein synthesis inhibitor, disrupting fungal cell function by targeting ribosomal processes. The drug represents a non-azole alternative for patients with nail fungus who may have limited options or contraindications to systemic therapy.
$0.019BPart D
PeakKERYDIN is in peak lifecycle stage with modest Part D utilization, suggesting a stable but not rapidly expanding franchise requiring maintenance-focused commercial teams rather than high-growth investment.
Mechanism of Action
Protein Synthesis Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Started Oct 2015
55 enrolled
OnychomycosisTinea Unguium
Career Relevance
KERYDIN offers career opportunities primarily in commercial and medical affairs roles supporting a mature, stable product in the dermatology space. Working on this brand emphasizes market penetration, payer relations, and field execution rather than launch dynamics or breakthrough innovation.
Brand Manager
Worked on KERYDIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.